Table 1.
Patient cohort characteristics
| IRIS | Non-IRIS | |
|---|---|---|
| N | 19 | 48 |
| Age at ART initiation, y* | 35.5 (30.4-43.3) | 36.5 (32.6-40) |
| Male, % | 63.2 | 83.3 |
| Pre-ART | ||
| PVL, log10* | 5.11 (4.76-5.39) | 5.11 (4.7-5.38) |
| CD4+ cells/μL* | 14 (6-47) | 22 (10-39) |
| CD8+ cells/μL* | 333 (230-692) | 391 (238-639) |
| Coinfections, % (no. of IRIS events)† | 94.7 | 64.6 |
| CMV | 15.8 (1u) | 12.5 |
| C neoformans | 10.5 (1p, 1u) | 6.3 |
| EBV | 5.3 (1u) | 2.1 |
| HBV | 5.3 (1p) | 12.5 |
| HHV-8 | 10.5 (1p, 1u) | 2.1 |
| H capsulatum | 10.5 (1p) | 4.2 |
| HPV | 26.3 (1p) | 16.7 |
| JCV | 5.3 (1u) | 0 |
| MAC | 31.6 (2p, 4u) | 6.3 |
| S stercoralis | 10.5 (1u) | 6.3 |
| TB | 21.1 (2p) | 16.7 |
| VZV | 15.8 (1p) | 20.8 |
| ART regimen component, % | ||
| NNRTIs | 68.4 | 52.1 |
| PIs | 31.6 | 47.9 |
| Ethnicity, % | ||
| Black | 52.6 | 47.9 |
| American Indian | 0 | 2.1 |
| Asian | 0 | 2.1 |
| White | 15.8 | 20.8 |
| Mixed | 10.5 | 12.5 |
PVL indicates plasma viral load; p, paradoxical IRIS; u, unmasking IRIS; NNRTIs, non-nucleoside reverse-transcriptase inhibitors; and PIs, protease inhibitors.
*
Median (interquartile range).
†
Only those OIs associated with IRIS events in this study were considered. P = .0138. None of the other parameters was statistically different between patient groups; individual infections were not tested for statistical significance.